CORONAVIRUS DISEASE - 19 – A SERIOUS THREAT TO PUBLIC HEALTH
The year 2020 is a public health emergency period declared globally by the WHO when on March 11, 2020, the deadly novel coronavirus-2019 causing severe acute respiratory syndrome (SARS) extended its stride in almost 150 countries commenced from Wuhan wet market, China led to declare globally as pandemic disease. Till date, more than 3 million are worldwide infected and the number is still in progression and nearly 200,000 people have succumbed, nearly 50,000 people only in United State died of this virus. Hence, this virus has brought global disaster. Therefore, this review is attempting to present a picture on coronavirus disease (COVID)-19 in terms of epidemiology, pathophysiology, and diagnosis, treatment, on the basis of available literature after search from the renowned database, especially focusing on public health impact. Treatment strategy is most essential part to focus for public health management and to save more life from this pandemic. As of date, there are no specific drugs for its treatment only repurpose drugs are employed for the hospitalized patient in present scenario, for example, Remdesivir made for Ebola is being use now in Covid-19 which inhibit replicase enzyme and reduced viral load, chloroquine and hydroxychloroquine an antimalarial drugs which prevent binding of S1 domain of Spike protein of SARS coronavirus 2 with Angiotensin Converting Enzyme-2 receptor and prevent fusion by S2 subunit thus overall prevent entering into the human susceptible cells along with it increases endosomal unstability by increasing pH. In addition, supportive care management such as supplemental oxygen and mechanical ventilation procedure is highly supportive to the critical patient. There infected more than 10 million people with more than 0.5 million death, the observation of July 7, 2020.
2. Jianxing T. ????”???”?????????. Caixin (in Chinese); 2020.
3. Xinhua. China’s CDC Detects a Large Number of New Coronaviruses in the South China Seafood Market in Wuhan. Available from: https://www.xinhuanet.com/2020-01/27/c_1125504355.htm. [Last accessed on 2020 Feb 20].
4. Yang P, Wang X. COVID-19: A new challenge for human beings. Cell Mol Immunol 2020;31:1-3.
5. Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020;87:281-6.
6. Chatterjee P, Nagi N, Agarwal A, Das B, Banerjee S, Sarkar S, et al. The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence. Indian J Med Res 2020;151:147-59.
7. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res 2011;81:85-164.
8. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J 2020;55:2000607.
9. Ramphul K, Mejias SG. Coronavirus disease: A review of a new threat to public health Cureus 2020;12:e7276.
10. Cai J, Xu J, Lin D, Yang Z, Xu L, Qu Z, et al. A case series of children with 2019 novel coronavirus infection: Clinical and epidemiological features. Clin Infect Dis 2020;2020:ciaa198.
11. Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections-the state of the art. Emerg Microbes Infect 2020;9:747-56.
12. Li H, Liu SM, Yu XH, Tang SL, Tanga CK. Coronavirus disease 2019 (COVID-19): Current status and future perspectives. Int J Antimicrob Agents 2020;55:105951.
13. Li Y, Xia L. Coronavirus disease 2019 (COVID-19): Role of chest CT in diagnosis and management. AJR Am J Roentgenol 2020;214:1280-6.
14. Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TM, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology 2020;296:E46-54.
15. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:732-9.
16. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
17. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020;9441:30390-7.
18. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81.
19. Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official ERS/ATS clinical practice guidelines: Noninvasive ventilation for acute respiratory failure. Eur Respir J 2017;50:1602426.
20. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020;9:727-32.
21. European Medicines Agency. EMA Gives Advice on the Use of Non-steroidal Anti-inflammatories for COVID-19. Available from: https://www.ema.europa.eu/en/news/emagives-advice-use-non-steroidal-anti-inflammatories-covid-19. [Last accessed on 2020 Mar 25].
22. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.
23. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown JA, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222.
24. Chang D, Xu H, Rebaza A, Sharma L, Cruz CS. Protecting health-care workers from subclinical coronavirus infection. Lancet Respir Med 2020;8:e13.
25. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2.
26. Wang J, Nikrad MP, Phang T, Gao B, Alford T, Ito Y, et al. Innate immune response to influenza a virus in differentiated human alveolar Type II cells. Am J Respir Cell Mol Biol 2011;45:582-91.
27. Rockx B, Baas T, Zornetzer GA, Haagmans B, Sheahan T, Frieman M, et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol 2009;83:7062-74.
28. Mossel EC, Wang J, Jeffers S, Edeen KE, Wang S, Cosgrove GP, et al. SARS-CoV replicates in primary human alveolar Type II cell cultures but not in Type I-like cells. Virology 2008;372:127-35.
29. Weinheimer VK, Becher A, Tonnies M, Holland G, Knepper J, Bauer TT, et al. Influenza a viruses target Type II pneumocytes in the human lung. J Infect Dis 2012;206:1685-94.
30. Kumar PA, Hu Y, Yamamoto Y, Hoe NB, Wei TS, Mu D, et al. Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell 2011;147:525-38.
31. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
32. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med 2020;58:1070-6.
33. Lagier JC, Colson P, Dupont HT, Salomon J, Doudier B, Aubry C, et al. Testing the repatriated for SARS-Cov2: Should laboratory-based quarantine replace traditional quarantine? Travel Med Infect Dis 2020;34:101624.
34. Won J, Lee S, Park M, Kim TY, Park MG, Choi BY, et al. Development of a laboratory-safe and low-cost detection protocol for SARS-CoV-2 of the coronavirus disease 2019 (COVID-19). Exp Neurobiol 2020;29:107-19.
35. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology 2020;296:E32-40.
36. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel coronavirus infection in hospitalized infants under 1 year of age in China. JAMA 2020;323:1313-4.
This work is licensed under a Creative Commons Attribution 4.0 International License.